Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$5.34 - $12.79 $347,100 - $831,350
-65,000 Reduced 10.67%
544,196 $5.74 Million
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $331,500 - $633,100
-65,000 Reduced 9.64%
609,196 $3.31 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $10.6 Million - $20.4 Million
674,196 New
674,196 $16.1 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Memorial Sloan Kettering Cancer Center Portfolio

Follow Memorial Sloan Kettering Cancer Center and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Memorial Sloan Kettering Cancer Center, based on Form 13F filings with the SEC.

News

Stay updated on Memorial Sloan Kettering Cancer Center with notifications on news.